Compare FTAI Aviation Ltd (FTAI) vs TG Therapeutics Inc (TGTX) Price & Performance

FTAI Aviation trades at $171.06, down 2.16% on the day amid a bearish technical signal. The stock has missed earnings estimates for three consecutive quarters, though revenue growth remains robust, rising to $3.1B in 2026. Recent developments include a $500M share repurchase program and a strategic acquisition of 27 Boeing 737-700 aircraft, signaling management's confidence and expansion efforts.

The outlook is mixed: strong analyst consensus (100% buy ratings) and a high price target of $321.25 suggest significant upside, but recent earnings misses, negative operating cash flow, and a high P/E of 37.35 pose risks. Investors should weigh growth initiatives against execution challenges and valuation concerns.

TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.

The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.